CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Ganciclovir

更昔洛韦 杂质对照品Ganciclovir Impurities

EP22 个杂质条目22 impurity entries

本页汇总 更昔洛韦 的 22 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 22 impurity reference standards of Ganciclovir with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 更昔洛韦(Ganciclovir)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesIdentification and characterization of unknown photo-oxidation degradation components of ganciclovir by high-performance liquid chromatography and quadrupole time-of-flight mass spectrometry
    European journal of mass spectrometry (Chichester, England) · 2026 · Pinapala S et al.  ·  PMID 41919566  ·  DOI
  2. 杂质研究Impurity studiesSustainable RP-HPLC Method Development Using AQbD Approach for Simultaneous Estimation of Valganciclovir Hydrochloride and Piperine-Loaded Lipid Nanoparticles
    Biomedical chromatography : BMC · 2026 · Mahalkari A et al.  ·  PMID 41980886  ·  DOI
  3. 杂质研究Impurity studiesAn Alternative Approach to Isoganciclovir: A Prominent Impurity in the Antiviral Drug Ganciclovir
    Scientia pharmaceutica · 2015 · Sundaram DT et al.  ·  PMID 26839813  ·  DOI
  4. 杂质研究Impurity studiesComparison of pharmaceutical quality of eight generic ganciclovir injections in China and Cymevene
    Journal of chemotherapy (Florence, Italy) · 2018 · Hong C, Wang J  ·  PMID 30843773  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisInhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information
    Antimicrobial agents and chemotherapy · 1987 · St Clair MH et al.  ·  PMID 3039910  ·  DOI

更昔洛韦 —— 原料药与杂质对照品Ganciclovir — drug substance & impurities

共 23 个条目(含原料药本体)23 items incl. the drug substance
Ganciclovir structure
EP原料药 APIAPI
更昔洛韦Ganciclovir
Ganciclovir
CAS No.82410-32-0
Chemical FormulaC9H13N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 1 (Ganciclovir EP Impurity A) structure
EPA
更昔洛韦杂质1 (更昔洛韦EP杂质A)Ganciclovir Impurity 1 (Ganciclovir EP Impurity A)
Ganciclovir Impurity 1 (Ganciclovir EP Impurity A)
CAS No.1797982-93-4
Chemical FormulaC9H10ClN5O2
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 2(Ganciclovir EP Impurity B) structure
EPB
更昔洛韦杂质2(更昔洛韦EP杂质B)Ganciclovir Impurity 2(Ganciclovir EP Impurity B)
Ganciclovir Impurity 2(Ganciclovir EP Impurity B)
CAS No.194159-18-7
Chemical FormulaC12H17N5O5
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 3(Ganciclovir EP Impurity C) structure
EPC
更昔洛韦杂质3(更昔洛韦EP杂质C)Ganciclovir Impurity 3(Ganciclovir EP Impurity C)
Ganciclovir Impurity 3(Ganciclovir EP Impurity C)
CAS No.108436-36-8
Chemical FormulaC9H12ClN5O3
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 4(Ganciclovir EP Impurity D) structure
EPD
更昔洛韦杂质4(更昔洛韦EP杂质D)Ganciclovir Impurity 4(Ganciclovir EP Impurity D)
Ganciclovir Impurity 4(Ganciclovir EP Impurity D)
CAS No.1346598-14-8
Chemical FormulaC10H15N5O5
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 5(Ganciclovir EP Impurity E) structure
EPE
更昔洛韦杂质5(更昔洛韦EP杂质E)Ganciclovir Impurity 5(Ganciclovir EP Impurity E)
Ganciclovir Impurity 5(Ganciclovir EP Impurity E)
CAS No.86357-09-7
Chemical FormulaC9H13N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 6(Ganciclovir EP Impurity F) structure
EPF
更昔洛韦杂质6(更昔洛韦EP杂质F)Ganciclovir Impurity 6(Ganciclovir EP Impurity F)
Ganciclovir Impurity 6(Ganciclovir EP Impurity F)
CAS No.73-40-5
Chemical FormulaC5H5N5O
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 7(Ganciclovir EP Impurity H) structure
EPH
更昔洛韦杂质7(更昔洛韦EP杂质H)Ganciclovir Impurity 7(Ganciclovir EP Impurity H)
Ganciclovir Impurity 7(Ganciclovir EP Impurity H)
CAS No.84222-50-4
Chemical FormulaC9H13N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 8(Ganciclovir EP Impurity I) structure
EPI
更昔洛韦杂质8(更昔洛韦EP杂质I)Ganciclovir Impurity 8(Ganciclovir EP Impurity I)
Ganciclovir Impurity 8(Ganciclovir EP Impurity I)
CAS No.86357-20-2
Chemical FormulaC15H21N5O6
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 9(Ganciclovir EP Impurity J) structure
EPJ
更昔洛韦杂质9(更昔洛韦EP杂质J)Ganciclovir Impurity 9(Ganciclovir EP Impurity J)
Ganciclovir Impurity 9(Ganciclovir EP Impurity J)
CAS No.177216-32-9
Chemical FormulaC18H25N5O7
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity C08 structure
C08
更昔洛韦杂质C08Ganciclovir Impurity C08
Ganciclovir Impurity C08
CAS No.84245-12-5
Chemical FormulaC11H15N5O5
Purity>95%现货In stock
10mg25mg50mg100mg
Ganciclovir Impurity 10 structure
10
更昔洛韦杂质10Ganciclovir Impurity 10
Ganciclovir Impurity 10
CAS No.1042148-94-6
Chemical FormulaC10H15N5O3
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 11 structure
11
更昔洛韦杂质11Ganciclovir Impurity 11
Ganciclovir Impurity 11
CAS No.81475-40-3
Chemical FormulaC9H13N5O3
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 12 structure
12
更昔洛韦杂质12Ganciclovir Impurity 12
Ganciclovir Impurity 12
CAS No.19916-73-5
Chemical FormulaC12H11N5O
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 13 structure
13
更昔洛韦杂质13Ganciclovir Impurity 13
Ganciclovir Impurity 13
CAS No.86357-14-4
Chemical FormulaC15H19N5O7
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 15 structure
15
更昔洛韦杂质15Ganciclovir Impurity 15
Ganciclovir Impurity 15
CAS No.175865-61-9
Chemical FormulaC14H22N6O5·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 16 structure
16
更昔洛韦杂质16Ganciclovir Impurity 16
Ganciclovir Impurity 16
CAS No.90661-36-2
Chemical FormulaC13H17N5O6
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 17 structure
17
更昔洛韦杂质17Ganciclovir Impurity 17
Ganciclovir Impurity 17
CAS No.109082-85-1
Chemical FormulaC47H41N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 18 structure
18
更昔洛韦杂质18Ganciclovir Impurity 18
Ganciclovir Impurity 18
CAS No.441349-84-4
Chemical FormulaC11H13Cl2N5O3
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 19 structure
19
更昔洛韦杂质19Ganciclovir Impurity 19
Ganciclovir Impurity 19
CAS No.441349-85-5
Chemical FormulaC9H11Cl2N5O2
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 20 structure
20
更昔洛韦杂质20Ganciclovir Impurity 20
Ganciclovir Impurity 20
CAS No.108436-45-9
Chemical FormulaC10H15N5O4
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 21 structure
21
更昔洛韦杂质21Ganciclovir Impurity 21
Ganciclovir Impurity 21
CAS No.86761-38-8
Chemical FormulaC9H16N5O13P3
Purity>95%询价On request
10mg25mg50mg100mg
Ganciclovir Impurity 26 structure
26
更昔洛韦杂质26Ganciclovir Impurity 26
Ganciclovir Impurity 26
CAS No.2640286-06-0
Chemical FormulaC13H16ClN5O5
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

更昔洛韦 —— 研究文献与合成路线Ganciclovir — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 更昔洛韦 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Ganciclovir. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Chemical and enzymatic degradation of ganciclovir prodrugs: enhanced stability of the diadamantoate prodrug under acid conditions
    Powell MF, Magill A, Chu N, et al. · Pharmaceutical research · 1991 · 被引 6cited 6
  2. Hydrolytic degradation and drug release properties of ganciclovir-loaded biodegradable microspheres
    Chen X, Ooi CP · Acta biomaterialia · 2008 · 被引 17cited 17
  3. Effect of ganciclovir on the hydrolytic degradation of poly(lactide-co-glycolide) microspheres
    Chen X, Ooi CP, Lim TH · Journal of biomaterials applications · 2006 · 被引 15cited 15
  4. Identification and characterization of unknown photo-oxidation degradation components of ganciclovir by high-performance liquid chromatography and quadrupole time-of-flight mass spectrometry
    Pinapala S, Pagala B, Ummiti K · European journal of mass spectrometry (Chichester, England) · 2026
  5. An Alternative Approach to Isoganciclovir: A Prominent Impurity in the Antiviral Drug Ganciclovir
    Sundaram DT, Kamat AG, Prabahar KJ, et al. · Scientia pharmaceutica · 2015
  6. Utility of certain sigma- and pi-acceptors for the spectrophotometric determination of ganciclovir in pharmaceutical formulations
    Gouda AA · Talanta · 2009 · 被引 4cited 4

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE ISOLATION OF GANCICLOVIR INTERMEDIATE
    PARTHASARADHI REDDY BANDI, RATHNAKAR REDDY KURA, MURALIDHARA REDDY DASARI, RAJI REDDY RAPOLU, et al. · 公开号 WO2011114336WO2011114336 · 2011
  2. Ganciclovir purification process
    YONGZHONG QIN, JINGLI WANG, CAOQIN ZHOU · 公开号 CN101851240CN101851240 · 2010
  3. PROCESS FOR THE PREPARATION OF GANCICLOVIR
    KHANDURI CHANDRA HAS, RAY PURNA CHANDRA, KUMAR YATENDRA, BABU JAYACHANDRA SURESH · 公开号 AU2003278420AU2003278420 · 2004
  4. PROCESS FOR THE PREPARATION OF GANCICLOVIR
    BABU Jayachandra Suresh, RAY Purna Chandra, KHANDURI Chandra Has, KUMAR Yatendra · 公开号 WO2004039808WO2004039808 · 2004
  5. PROCESS FOR THE PREPARATION OF GANCICLOVIR
    BABU Jayachandra Suresh, RAY Purna Chandra, KHANDURI Chandra Has, KUMAR Yatendra · 公开号 EP1565470EP1565470 · 2005

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

更昔洛韦 杂质谱研究要点Ganciclovir — impurity profiling notes

下面这些是拿到 更昔洛韦 的 23 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 23 impurity entries for Ganciclovir, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances